Financing channel feed – Endpoints News

Financing channel feed

Months after a mammoth raise, Ventyx Biosciences dips back into venture well

4 years ago

Chinese CAR-T player books a megaround to drive bustling cell therapy portfolio through the clinic

4 years ago

The Ariad vets developing next-gen TKIs are heading back to Nasdaq — and OrbiMed stands to reap the most

4 years ago

Endocrine-focused biotech gets new cash for its peptides, with dreams of launching a franchise

4 years ago

Pfizer backs a small Swiss upstart's attempt to discover a non-viral gene therapy

4 years ago

Three more biotechs hit Nasdaq as the sector, now with more than $13B raised, continues barreling toward record

4 years ago

Pain player Allay makes good on launch promises, locking down latest fundraising round to advance lead implant

4 years ago

The team behind eFFECTOR's SPAC deal is back after going from launch to merger in just 4 months

4 years ago

Shanghai biotech tackling kidney disease gets another round of cash

4 years ago

Bill Haney adds another $133M to Skyhawk's coffers, as the RNA startup guns for the clinic

4 years ago

Spurred on by OrbiMed partner's diagnosis, Vanqua Bio takes aim at neurodegenerative disease with blue-chip backers

4 years ago

Lightstone Ventures unveils $375M third fund, this time expanding its wishlist in blossoming CNS field

4 years ago

Rosana Kapeller raises $77M in bid to make repeatome drugs a reality

4 years ago

French biotech raises $75M for new cell therapy manufacturing tech, Parkinson's treatment

4 years ago

Five Prime founder Rusty Williams sets out to test the limits of cell therapy with axolotl-inspired biotech

4 years ago

Exscientia tees up an IPO for its AI drug discovery platform, likely not willing to settle for just $100M

4 years ago

IPO filings are back on the biotech menu as an ADHD drug developer submits its Nasdaq paperwork

4 years ago

A longevity researcher and wealthy backers launch fast grants to fund ‘crazy ideas’ in anti-aging research

4 years ago

A new player joins the RNA editing race on the heels of Eli Lilly's $1B-plus deal

4 years ago

Jennifer Doudna's diagnostic spinout raises Mammoth round as it expands to therapies

4 years ago

A new clutch of biotech blue-chippers joins Obsidian's quest to craft next-gen drugs with an 'on' switch

4 years ago

After getting their candidates back from Eli Lilly, the old Dermira team is dashing for the clinic

4 years ago

Eli Lilly-backed Lycia fuels up on VC cash in a discovery drive toward protein degradation 2.0

4 years ago

The Tachi Yamada legacy tree continues to grow with a new gene editing biotech from Jim Wilson

4 years ago

First page Previous page 66 67 686970 71 72 Next page Last page